Overview

Phase I/IIa Study of 68GaNOTA-Anti-MMR-VHH2 for PET/CT

Status:
Recruiting

Trial end date:
2023-04-01

Target enrollment:

Participant gender:

Summary

Phase I/IIa study to evaluate the uptake of 68NOTA-anti-MMR-VHH2, a new tracer for positron emission tomographic imaging (PET/CT scan) of breast cancer, head and neck cancer or melanoma

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Universitair Ziekenhuis Brussel

Collaborator:

Kom Op Tegen Kanker

Treatments:

Radiopharmaceuticals